Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Mats Jerkeman, MD PhD, Arne Kolstad, MD PhD, Carsten Utoft Niemann, MD PhD, Kirsten Groenbaek, MD DMSc, Martin Hutchings, MD PhD, Annika Pasanen, MD PhD, Sara Ekberg, Karin Fahl Wader, MD PhD, Ingrid Glimelius, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133273

Published: 2020

Journal Articles

Unraveling Actionable Target Mutations in Formalin Fixed Tissue in Mantle Cell Lymphoma

Joana M. Rodrigues, May Hassan, Msc., Anna Porwit, Sara Ek, PhD Professor, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136944

Published: 2020

Journal Articles

Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL C omplete Project

Mats Jerkeman, MD PhD, Thorgerdur Palsdottir, Ingrid Glimelius, MD PhD, Alexandra Albertsson-Lindblad, MD PhD, Caroline Weibull, Fredrik Ellin, MD PhD, Kristina Sonnevi, MD PhD, Catharina Lewerin, MD PhD, Lena Brandefors, Karin E. Smedby, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-133292

Published: 2020

Journal Articles

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Åsa Lindberg, III, Christian Winther Eskelund, Alexandra Albertsson-Lindblad, MD PhD, Arne Kolstad, MD PhD, Anna Laurell, MD PhD, Riikka Räty, MD PhD, Kirsten Grønbæk, Prof,MDDMSc, Christian H. Geisler, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133370

Published: 2020

Journal Articles

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Karin Fjorden, Sara Ekberg, Nevzeta Kuric, Karin Ekstroem Smedby, Ingemar Lagerlöf, MD, Thomas S. Larsen, MD, Judit M. Jørgensen, MD PhD, Peter de Nully Brown, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-133359

Published: 2020

Journal Articles

17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Mats Jerkeman, MD PhD, Andres McAllister, MD PhD, Carl Roos, Marie Lindell Andersson, Ingrid Karlsson, PhD, Marie Borggren, PhD, Pau Abrisqueta, MD PhD, Ana Carneiro, MD PhD, Raul Cordoba, MD PhD, Hans Hagberg, MD, Santiago Mercadal, MD, Ingrid Teige, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140219

Published: 2020

Journal Articles

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Marie Borggren, PhD, Mathilda Kovacek, Carl Roos, Therese Blidberg, Robert Oldham, PhD, Mats Jerkeman, MD PhD, Martin J.S. Dyer, MD PhD, Andrew Davies, MD PhD, Raul Córdoba, MD PhD, Pau Abrisqueta, MD PhD, Stephen Beers, PhD, Ingrid Teige, PhD, Andres McAllister, MD PhD, Sean H Lim, MD PhD, Mark S Cragg, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138658

Published: 2020

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, MD PhD, Martin Hutchings, MD PhD, Riikka Räty, MD PhD, Karin Fahl Wader, MD PhD, Anna Laurell, MD PhD, Jacob H. Christensen, MD, Hanne Kuitunen, MD, Christian Winther Eskelund, MD PhD, Kirsten Groenbaek, MD DMSc, Carsten Utoft Niemann, MD PhD, Christian H. Geisler, MD PhD, Arne Kolstad, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-133298

Published: 2020

Journal Articles

Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study

Monica Mead, MD BS, Henrik Cederleuf, MD, Thomas Relander, MD PhD, Mats Jerkeman, MD PhD, Fredrik Ellin, MD PhD, Daria Gaut, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134814

Published: 2020

Journal Articles

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Karin Ekstroem Smedby, Sara Harrysson, MD, Sara Ekberg, Mats Jerkeman, MD PhD, Per-Ola Andersson, MD PhD, Gunilla Enblad, Sandra Eloranta

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138737

Published: 2020

Journal Articles

Ibrutinib in Combination with Anti-CD20-Antibody Negatively Affects Antibody Dependent Cellular Cytotoxic (ADCC) on Mantle Cell Lymphoma Cell Lines, Not Reversed By the Addition of Lenalidomide

Mats Jerkeman, MD PhD, Sara Ek, PhD, Catja Freiburghaus, PhD, Alexandra Albertsson Lindblad

Blood (2017) 130 (Supplement 1): 1266.

https://doi.org/10.1182/blood.V130.Suppl_1.1266.1266

Published: 2017

Journal Articles

Evaluation of the NCCN-IPI As a Prognostic Tool in PTCLs

Fredrik Ellin, MD MSc, Matthew J Maurer, MS, Line Srour, MD, Umar Farooq, MD, Mats Jerkeman, MD PhD, Joseph M Connors, MD, Karin E Smedby, MD PhD, Nabila Nora Bennani, MD, Stephen M Ansell, MD PhD, Graham W Slack, MD, James R. Cerhan, MD PhD, Thomas Relander, MD PhD, Andrew L Feldman, MD, Kerry J Savage, BSc, MD MSc

Blood (2017) 130 (Supplement 1): 2795.

https://doi.org/10.1182/blood.V130.Suppl_1.2795.2795

Published: 2017

Journal Articles

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Tove Wästerlid, MD PhD, Jorne Lionel Biccler, MSc, Peter de Nully Brown, MD PhD, Jacob Haaber Christensen, MD PhD, Gunilla Enblad, MD PhD, Judit Mészáros Jørgensen, Karin E Smedby, MD PhD, Tarec Christoffer El-Galaly, MD PhD, Mats Jerkeman, MD PhD

Blood (2017) 130 (Supplement 1): 1560.

https://doi.org/10.1182/blood.V130.Suppl_1.1560.1560

Published: 2017

Journal Articles

Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma

Tove Wästerlid, MD, Lena Nordström, MSc, PhD, Mette Pedersen, MD PhD, Peter H Norgaard, MD PhD, Anne Ortved Gang, MDPhD, Peter de Nully Brown, MDPhD, Mats Jerkeman, MD PhD, Sara Ek, PhD

Blood (2015) 126 (23): 5039.

https://doi.org/10.1182/blood.V126.23.5039.5039

Published: 2015

Journal Articles

Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration

Chan Yoon Cheah, MBBS DMedSc, Paul J Broeckelmann, MD, Alison J Moskowitz, MD, Andreas Engert, MD, Mats Jerkeman, MD PhD, Tarec Christoffer El-Galaly, Julie Vose, Diego Villa, MDMPH, Joseph M. Connors, MD, Tatyana Feldman, MD, Dai Chihara, MD PhD, Chelsea C Pinnix, MDPhD, Sarah A Milgrom, MD, Bouthaina S. Dabaja, MD, Yasuhiro Oki, MD, Michelle A. Fanale, MD

Blood (2015) 126 (23): 3865.

https://doi.org/10.1182/blood.V126.23.3865.3865

Published: 2015

Journal Articles

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Blood (2015) 126 (23): 469.

https://doi.org/10.1182/blood.V126.23.469.469

Published: 2015

Journal Articles

Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort

Kristina Drott, MD PhD, Hans Hagberg, MD PhD, Thomas Relander, MD PhD, Cecilia Graffman, MD PhD, Johan Drott, PhD, Mats Jerkeman, MD PhD

Blood (2015) 126 (23): 3939.

https://doi.org/10.1182/blood.V126.23.3939.3939

Published: 2015

Journal Articles

Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Henrik Cederleuf, MD, Martin BjerregÃ¥rd Pedersen, MD PhD, Mats Jerkeman, MD PhD, Thomas Relander, MD PhD, Francesco d'Amore, MD, Fredrik Ellin, MD MSc

Blood (2015) 126 (23): 340.

https://doi.org/10.1182/blood.V126.23.340.340

Published: 2015

Journal Articles

Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma

Matthew J Maurer, MS, Fredrik Ellin, MD MSc, James Cerhan, MD PhD, Stephen Ansell, MD PhD, Brian K Link, MD, Mats Jerkeman, MD PhD, Karin E Smedby, MD PhD, Carrie A. Thompson, MD, William Macon, MD, Sergei Syrbu, MD, Susan L. Slager, PhD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Thomas Relander, MD PhD, Andrew L Feldman, MD

Blood (2015) 126 (23): 1501.

https://doi.org/10.1182/blood.V126.23.1501.1501

Published: 2015

Journal Articles

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Georg Hess, MD, Simon Rule, MD, Wojciech Jurczak, Mats Jerkeman, MD PhD, Rodrigo Santucci, MD, Chiara Rusconi, MD, Dolores Caballero, Cristina M. Joao, MD PhD, Mathias Witzens-Harig, MD, Isabelle Bence-Bruckler, MD FRCPC, Seok-Goo Cho, Nibedita Bandyopadhyay, PhD, Jenna Goldberg, MD, John Bothos, PhD, Christopher Enny, BS, Jessica Vermeulen, MD PhD, Shana Traina, PhD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 1542.

https://doi.org/10.1182/blood.V126.23.1542.1542

Published: 2015

NARROW

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Unraveling Actionable Target Mutations in Formalin Fixed Tissue in Mantle Cell Lymphoma

Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL C omplete Project

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Ibrutinib in Combination with Anti-CD20-Antibody Negatively Affects Antibody Dependent Cellular Cytotoxic (ADCC) on Mantle Cell Lymphoma Cell Lines, Not Reversed By the Addition of Lenalidomide

Evaluation of the NCCN-IPI As a Prognostic Tool in PTCLs

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma

Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort

Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only